Fierce Biotech
Novo Nordisk prepares to go global as triple-G prospect passes midphase diabetes test in China
Novo Nordisk and its Chinese partner have reported another midphase win for their triple G candidate, sharing diabetes data to add to the momentum generated by an obesity readout. But while the data suggest the asset is competitive, Eli Lilly’s headstart in the space means it remains the company to beat.